- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06072859
The Impact of Simulated Forest Immersion Therapy on Pain and Anxiety in Patients Axial Spondyloarthritis (axSpA)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
DURATION:
Participation in the study will consist of 1 visit total and will last up to 2 consecutive hours.
PROCEDURES:
Participants will be randomized to receive either the forest oils only, or the forest oils and audio-visual forest exposure described above for up to 1 hour.
Study Visit:
- During Visit 1 and the only study visit, the investigator will explain the study and obtain consent. The Investigator will explain this study and answer any questions the participant may have. The participant will have the opportunity to review this document in detail.
- Consent may be withdrawn by the participant at any time during the study.
- Once the written consent is signed, the participant will be asked to rest for 15 minutes.
- During the resting period, randomization will occur into one of two groups:
- Group 1 - Forest oils only, or
- Group 2 - Forest oils and audio-visual forest exposure
- Following the resting period, demographics will be collected from the participants.
- The investigators will then take a blood pressure and heart rate measurement.
- Then, the investigator will ask the participants to fill out two questionnaires. One of these questionnaires consists of two questions asking the participants about their pain level and location, the other questionnaire asks about mood state and how the participants rate various qualities of their feelings. The third questionnaire asks the participants about their pain levels specific to the past week.
- Participants will then be taken into the study room where they will participate in the simulated forest experience.
- If the participants are randomly assigned to Group 1, they will be breathing in the aroma of the forest oils for a period of 1 hour in the study room. There is an adjustable lounge chair in the room to sit in. And the participants may read or use their phone quietly.
- If the participants are randomly assigned to Group 2, they will be breathing in the aroma of the forest oils for a period of 1 hour in the study room while using the headphones and tablet with the simulated forest greenspace sights and sounds. There is an adjustable lounge chair in the room to sit in.
- The investigator will take the participants blood pressure and heart rate measurement after 30 minutes from the start of the intervention.
- Within 15 minutes following the simulated experience in the study room, the investigator will take one more blood-pressure and heart rate measurement. Then, the participants will fill out the same two questionnaires again, which are asking the participants about their pain level and location and mood.
- The investigators will then ask the participants some questions about the participants' experience before the end of the study visit.
- One week after the participants study visit (Study Visit 1), the investigator will ask the participants to return two follow-up questionnaires to us over encrypted and password protected OHSU email, or by arranging to drop the questionnaires off with the Study Coordinator or the Rheumatology Clinic at OHSU.
RISKS: There are three risks to participation in this study and these are all considered minimal risks. Participants may have an allergic reaction, a cough, or an increase in asthma type symptoms, such as difficulty breathing related to the humidified fragrant citrus forest oil used in this study. For those in Group 2, the participants may experience a sensation of nausea (feeling queasy), discomfort related to the headphone placement, sound disturbances related to the volume of the nature sounds, or discomfort related to viewing the images of the forest greenspace environment utilized in this study. the investigators will make every effort to protect the participants privacy during this study, including password protected files, secure and encrypted email, and double locked file system. A loss of confidentiality happens when the participants private information is accessed outside the scope of this study. A loss of confidentiality is an unexpected event.
BENEFITS: Participants may not directly benefit from taking part in this research. However, participation will potentially benefit patients with Axial Spondyloarthritis in the future.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Oregon Health & Science University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- able to read at a 5th grad level
- medically diagnosed with Axial Spondyloarthritis
- tolerate having their BP and HR taken
- average of greater than 3 on their last recorded pain assessments
- average of greater than 4 on their last BASDI recorded
- currently have an assigned Rheumatologist in their care delivery
Exclusion Criteria:
- history of asthma
- currently pregnant
- inability to detect common odors from commercial fragrances
- smoking within 15 minutes of the start of the intervention procedure
- known allergy to citrus aroma
- hard of hearing without assistive devices
- limited vision not corrected by eye lenses
- history of hypertension uncontrolled by medications
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Group 1
Humidified Forest Oils with Limonene
|
60mls Limonene in 200mls water humidified with a diffuser.
|
Active Comparator: Group 2
Humidified Forest Oils with Limonene & Virtual Reality using a Surface Pro tablet with headphones to experience walking on a forest path and ambient forest sounds.
|
60mls Limonene in 200mls water humidified with a diffuser.
Surface Pro has a looped visual that can be manipulated by the participant to simulate walking on a forest path or through a forest visual.
This is paired with headphones to experience ambient forest sounds.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Axial Skeleton Pain
Time Frame: before intervention on visit 1, directly after intervention on visit 1, and one week later
|
Pain on Visual Analog Scale, Scores 0-10 with higher scores reflecting greater pain
|
before intervention on visit 1, directly after intervention on visit 1, and one week later
|
Anxiety
Time Frame: before intervention on visit 1, directly after intervention on visit 1, and one week later
|
Anxiety as scored on STAI - State only Higher scores mean greater state anxiety, 20 items with a scoring range of 1-4 on each of them.
Score is totaled and range 20-80 with higher scores reflecting higher anxiety as a state.
|
before intervention on visit 1, directly after intervention on visit 1, and one week later
|
Blood Pressure
Time Frame: before intervention on visit 1, after 30 minutes of the intervention start on visit 1, directly after intervention on visit 1, and one week later
|
Blood Pressure measured by Omnicron tabletop BP and HR device, used clinically, higher Blood Pressure, both systolic and diastolic pressures, measured reflect/correlate with higher anxiety or pain status.
Measure range 0-240.
|
before intervention on visit 1, after 30 minutes of the intervention start on visit 1, directly after intervention on visit 1, and one week later
|
Heart Rate
Time Frame: before intervention on visit 1, after 30 minutes of the intervention start on visit 1, directly after intervention on visit 1, and one week later
|
Heart Rate measured by Omnicron tabletop BP and HR device, used clinically, higher Heart Rate measured reflect/correlate with higher anxiety or pain status.
Measure range 0-300.
|
before intervention on visit 1, after 30 minutes of the intervention start on visit 1, directly after intervention on visit 1, and one week later
|
Feasibility Questions
Time Frame: directly after intervention on visit 1
|
Questions regarding the intervention include the tolerance of the intervention, likes and dislikes of the experience and any suggestions to make the intervention experience better.
|
directly after intervention on visit 1
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)
Time Frame: before intervention on visit 1, directly after intervention on visit 1, and one week later
|
Measures pain and functionality in Axial Spondyloarthritis by assessing individual metrics for fatigue, axial involvement, peripheral articular involvement, localized tenderness/enthesitis, and morning stiffness.
Score 0-10 with higher scores reflecting higher pain and functionality issues.
|
before intervention on visit 1, directly after intervention on visit 1, and one week later
|
Routine Assessment of Patient Index Data 3 (RAPID3)
Time Frame: before intervention on visit 1, directly after intervention on visit 1, and one week later
|
composite index which is routinely and reliably used to assess disease activity in Axial Spondyloarthritis.
Score range 0-30 with higher scores reflecting higher disease activity.
|
before intervention on visit 1, directly after intervention on visit 1, and one week later
|
Collaborators and Investigators
Investigators
- Principal Investigator: Amy Miner Ross, PhD, Oregon Health and Science University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 00025267
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Axial Spondyloarthritis
-
UCB Biopharma SRLCompletedNonradiographic Axial SpondyloarthritisUnited States, Belgium, Bulgaria, China, Czechia, France, Germany, Hungary, Japan, Poland, Spain, Turkey, United Kingdom
-
Novartis PharmaceuticalsRecruitingNon-radiographic Axial SpondyloarthritisBelgium, Netherlands, Italy, Thailand, Hungary, Malaysia, Germany, Israel, France, Czechia, Colombia, Romania, Poland, Turkey, Vietnam, Brazil, Mexico, Philippines
-
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...Not yet recruitingAxial SpondyloarthritisChina
-
Merck Sharp & Dohme LLCCompletedSpondyloarthritisCzechia, Germany, Netherlands, Poland, Romania, Russian Federation, Spain, Turkey, Ukraine
-
Novartis PharmaceuticalsActive, not recruitingNon-radiographic Axial SpondyloarthritisChina
-
UCB Biopharma SRLActive, not recruitingAnkylosing Spondylitis | Axial Spondyloarthritis | r-axSpa | Nr-axSpaUnited States, Belgium, Bulgaria, China, Czechia, France, Germany, Hungary, Japan, Netherlands, Poland, Spain, Turkey, United Kingdom
-
Bangabandhu Sheikh Mujib Medical University, Dhaka...Healthcare PharmaceuticalsRecruitingSpondyloarthritis, AxialBangladesh
-
Fondazione Policlinico Universitario Agostino Gemelli...Not yet recruitingSpondyloarthritis | Spondyloarthritis, AxialItaly
-
UCB BIOSCIENCES GmbHCompletedAxial Spondyloarthritis | Nonradiographic Axial Spondyloarthritis | Nr-axSpAUnited States, Australia, Bulgaria, Canada, Czechia, Hungary, Poland, Russian Federation, Taiwan
-
Centre Hospitalier Universitaire de BesanconNot yet recruitingSpondyloarthritis, AxialFrance
Clinical Trials on Humidified Forest Oils
-
Vilnius UniversityLinkoeping UniversityCompleted
-
Charite University, Berlin, GermanyRecruitingGeneral Population (no Specific Condition or Disease)Germany
-
University of British ColumbiaCompletedStress, Psychological | Anxiety | Blood Pressure | Mental Health Wellness 1 | Environmental Exposure | Nature, HumanCanada
-
Charite University, Berlin, GermanyCompletedGeneral PopulationGermany
-
Northwestern UniversityNot yet recruitingDepression | Burnout, Professional | Burnout | Compassion Fatigue | Anxiety | Job Stress | Positive AffectUnited States
-
Vilnius UniversityLinkoeping UniversityCompletedStress, PsychologicalLithuania
-
Vilnius UniversityLinkoeping UniversityCompleted
-
University Hospital, AngersUnknown
-
Johns Hopkins UniversityCompleted
-
Charite University, Berlin, GermanyRecruitingMetabolic Syndrome, Protection AgainstGermany